Top Markets
Coin of the day
Coeptis Therapeutics Holdings, Inc. Coeptis Therapeutics Holdings, Inc.

Coeptis Therapeutics Holdings, Inc.

COEP
株式のランク #28029
Coeptis Therapeutics Holdings, Inc., together with its subsidiaries, operates... Coeptis Therapeutics Holdings, Inc., together with its subsidiaries, operates as a biopharmaceutical and technology company. The company is developing cell therapy platforms for cancer, autoimmune, and infectious diseases. Its therapeutic portfolio includes an allogeneic cellular immunotherapy platform; and DVX201, a clinical-stage, unmodified natural killer cell therapy technology. The company’s product pipeline consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; CD38-Diagnostic, an in vitro screening tool to analyze cancer patients if cancer patients might be appropriate candidates for anti-CD38 mAb therapy; and SNAP-CAR, a chimeric antigen receptor (CAR) therapy for treatment for cancer. In addition, the company offers its drugs for acute myeloid leukemia and acute respiratory diseases. Coeptis Therapeutics Holdings, Inc. has co-development agreement Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson’s Disease. The company was founded in 2017 and is headquartered in Wexford, Pennsylvania.
株価
$4.81
最終同期: 2026-07-27
時価総額
$29.01M
変化(1日)
-8.56%
変化(1年)
-64.66%
US
取引 Coeptis Therapeutics Holdings, Inc. (COEP)

カテゴリー

Coeptis Therapeutics Holdings, Inc.(COEP)のP/S比率
2026 時点のP/S比率 TTM: 0
Coeptis Therapeutics Holdings, Inc. の最新の財務報告および株価によると、現在のP/S比率(TTM)は 0 です。2026 年末時点でのP/S比率は 0 でした。
Coeptis Therapeutics Holdings, Inc. の P/S 比率の履歴(2026 ~ 2026)
各年末時点のP/S比率
P/S比率 変化
提供された日付のデータは十分ではありません。
同業他社のP/S比率
企業 P/S比率 P/S比率の差
10.17 -
US
11.28 -
US
10.13 -
NL
2.95 -
AU
- -
CH